Oncolytic potential of autonomous parvoviruses

Abstract

Background. In many countries, more than 40 oncolytic viruses from 10 different families are undergoing clinical trials (phase I, II, III) against various types of cancer; some of them have already been approved for use. The results of the experimental studies that deal with the development of oncolytic drugs based on autonomous parvoviruses deserve special attention.
 Purpose. The purpose of the study was to analyze and summarize literature sources that are concerned with the development of oncolytic drugs based on autonomous parvoviruses.
 Materials and Methods. Publications were selected using keywords in PubMed (https://pubmed.ncbi.nlm.nih.gov/) and Google Scholar (https://scholar.google.com/) databases published over the period from 2010 to 2023.
 Results. Among autonomous parvoviruses, protoparvoviruses are the most promising for the development of anticancer drugs. They detect CPE mainly in tumor cells, CPE is absent or limited in non-transformed human and rodent cell lines. Many of them are capable of actively replicating in cancer cells without destroying normal body cells. They primarily block the pathways of activation of type I interferons. The main non-structural viral protein NS1 plays a significant role in the manifestations of oncolytic activity of protoparvoviruses.
 Conclusions. Numerous studies continue to be directed at studying the mechanisms associated with the oncolytic properties of autonomous parvoviruses. The use of recombinant parvoviruses allows their oncolytic potential to be enhanced.